Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(13%)

Phase Distribution

Ph phase_2

63%

Ph phase_1

38%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

3(37.5%)

Phase 2Efficacy & side effects

5(62.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(3)

Other(1)

Detailed Status

Completed4

Withdrawn2

Terminated1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (37.5%)

Phase 25 (62.5%)

Trials by Status

withdrawn225%

terminated113%

completed450%

unknown113%

Recent Activity

0 active trials

Showing 5 of 8

completedphase_2

A Phase 2 Extension Study of Study GCS-100-CS-4002

NCT02155673

completedphase_2

A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease

NCT01843790

unknownphase_2

A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes

NCT02312050

withdrawnphase_2

A Phase 2 Extension of Study GCS-100-CS-4003

NCT02333955

withdrawnphase_1

GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00776802

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT02155673Phase 2

A Phase 2 Extension Study of Study GCS-100-CS-4002

Completed

NCT01843790Phase 2

A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease

Completed

NCT02312050Phase 2

A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes

Unknown

NCT02333955Phase 2

A Phase 2 Extension of Study GCS-100-CS-4003

Withdrawn

NCT00776802Phase 1

GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Withdrawn

NCT00609817Phase 1

Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma

Terminated

NCT01717248Phase 1

Safety Study of GCS-100 to Treat Chronic Kidney Disease

Completed

NCT00514696Phase 2

Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8